COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 1 Study to Evaluate the Safety of BB2121 in Subjects with High Risk Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Protocol No
CELGENE-BB2121-MM-004-KARMMA4
Principal Investigator
Parameswaran Hari
Phase
I
Summary
This study is to determine if the investigational therapy called bb2121 is safe and to find the optimal dose to treat high risk-newly diagnosed multiple myeloma (HR NDMM) subjects.
Description
A Study to Evaluate the Safety of bb2121 in Subjects with High Risk NDMM (KarMMa4)
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL